



IAS – the International AIDS Society – is thrilled to announce the appointment of new Co-Chairs for the three groups in its [Corporate Partnership Programme](#) for the 2024-2026 term. These appointments mark a significant step forward in addressing the global HIV agenda, with renowned leaders in HIV treatment, prevention, vaccine research and cure strategies taking the helm. Their expertise will be pivotal in fostering meaningful collaborations and driving innovative solutions, furthering the IAS mission to tackle the ever-evolving challenges of the HIV response.

The **Corporate Partnership Programme** brings together IAS non-industry and industry partners to drive important conversations across the HIV continuum of care. Established with the flagship Industry Liaison Forum, the programme expanded in 2021 to include the Towards an HIV Cure: Industry Collaboration Group and the HIV Vaccine Industry Partnership Group, strengthening collaboration on critical needs in the HIV response. Each group provides opportunities for stakeholders to inform research agendas, accelerate the introduction of new technologies, and mobilize biomedical industry and non-industry partners – including academic, civil society and global health institutions – towards shared goals.

### **Industry Liaison Forum:**

The **Industry Liaison Forum** convenes biomedical industry and non-industry stakeholders, including community-based organizations, to engage on a broad range of topics vital to the pharmaceutical, diagnostics and related sectors in their responses to HIV.

[Felipe Rogatto](#), Executive Director of Global Medical Affairs – HIV at Gilead Sciences, and [Mitchell Warren](#), Executive Director of AVAC, are the new Co-Chairs of the Forum, succeeding Fernando Bognar and Nittaya Phanuphak.



[Felipe](#) brings over a decade of leadership in HIV care, working across Brazil, Mozambique and Canada. As the leader of Gilead's HIV Franchise, he has been key in addressing unmet needs in HIV treatment and prevention, driving innovation and client-focused outcomes.



[Mitchell](#), a global health advocate with nearly 30 years of experience in HIV prevention, has led AVAC's efforts to expand access to HIV prevention tools and has forged partnerships between scientists, policy makers and community advocates. His work has been instrumental in advancing HIV research and next-generation prevention methods.

### **HIV Vaccine Industry Partnership Group:**


The **HIV Vaccine Industry Partnership Group** brings together biomedical industry and non-industry stakeholders to tackle the complexities of HIV vaccine research and development.



[Tetsuro Matano](#), Deputy Director-General at the National Institute of Infectious Diseases in Japan, and [Shan Lu](#), Professor Emeritus at the University of Massachusetts Medical School and Chief Scientific Officer at Worcester HIV Vaccine, are the new Co-Chairs of the Vaccine group, succeeding Linda-Gail Bekker and Carey Hwang.



[Tetsuro](#) has pioneered research on HIV-specific immune responses using macaque models and has made significant advances in elucidation of the viral control mechanism by neutralizing antibodies and T-cell responses. His innovative work, including a novel HIV vaccine delivery system, has shown promising results in trials across Rwanda, Kenya and the UK.



[Shan](#), a global leader in vaccine science, has contributed over 30 years of pioneering research in DNA vaccine and heterologous prime-boost vaccination. He developed the world's first polyvalent HIV DNA/protein vaccine, and his work continues to push the boundaries of vaccine science and immune response.


### **Towards an HIV Cure: Industry Collaboration Group:**

The **Towards an HIV Cure: Industry Collaboration Group** fosters collaboration between biomedical industry and non-industry stakeholders to prioritize and drive forward research and development for an HIV cure.

[Sharon Lewin](#), Director of the Peter Doherty Institute for Infection and Immunity at the University of Melbourne, and [Devi SenGupta](#), Global Lead for HIV Cure Development at Gilead Sciences, are the new Co-Chairs of the Cure group, succeeding Bonnie Howell and Timothy Henrich.



[Sharon](#), a globally recognized leader in HIV cure research, has led groundbreaking work in HIV, hepatitis B and COVID-19. With over 350 published manuscripts, her contributions to the field of HIV cure strategies have been instrumental in pushing the science towards attaining long-term HIV remission.



[Devi](#), with her expertise in clinical development and translational research, oversees Gilead's HIV cure programme. She brings vast experience in leading groundbreaking trials aimed at achieving sustained HIV remission and has been a key figure in advancing treatment and cure research.



We sincerely thank **Fernando Bognar, Nittaya Phanuphak, Linda-Gail Bekker, Carey Hwang, Bonnie Howell** and **Timothy Henrich** for their outstanding leadership. We look forward to collaborating with the incoming Co-Chairs as they guide their groups toward new frontiers in advancing the global HIV agenda.